Get Adobe Flash player



Some two million people worldwide(1)

(1) Source: Inserm.
suffer from Multiple Sclerosis. Pharmaceutical companies play a crucial role in battling this disease, as do other stakeholders, such as patient organizations, pharmacists, hospitals, and public health authorities. This collective commitment has led to a significantly clearer understanding of this disease and there have been major therapeutic advances for many patients. The two new drugs developed by Sanofi Genzyme, our specialty care business unit, are among the treatments that can change patients’ lives. These cutting-edge treatments slow advancement of the disease, and Sanofi Genzyme now provides more convenience with an oral administration treatment besides the injectable one.

Tiger, a Multiple Sclerosis patient in the United Kingdom.



Vaccination campaign in Nepal.

The number of polio cases has decreased by more than 99% since 1988, dropping from 350,000 cases to just 74 cases reported in 2015(1).

(1) Source: World Health Organization.

This key milestone is the result of the persistent, worldwide commitment to fight this disease. In 1982, our vaccines unit, Sanofi Pasteur, registered the injectable polio vaccine (IPV), containing the inactivated polio virus and it is now distributed worldwide. Since 2014, by virtue of a partnership between Sanofi Pasteur and the Bill & Melinda Gates Foundation, the GAVI Alliance has made the IPV vaccine available to the most vulnerable populations at an affordable price. Doing so entailed substantial investments in technology on our part to produce large quantities of IPV in Marcy-l’Étoile, France. We also introduced a major registration program in nearly 100 countries. To date, we have distributed more than a billion doses of vaccines, both IPV and containing IPV, to protect hundreds of millions of children.